Zomedica Announces Presentation of Clinical Data in Support of New Indications for PulseVet Shock Wave Therapy at Annual Meeting of American Association of Equine Practitioners

ANN ARBOR, MI / ACCESSWIRE / December 6, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the presentation of new clinical data supporting new indications for shock wave therapy at the recent meeting of the American Association of Equine Practitioners (AAEP) annual meeting in San Diego, California.

Principal Investigator Dr. Beau Whitaker of Brazos Valley Equine Hospital (Salado, TX) presented results from the study showing that barrel racing horses with Exercise Induced Pulmonary Hemorrhage (EIPH) could be successfully treated with PulseVet's electrohydraulic shock wave therapy. In this study more than 75% of the horses treated showed significant improvement following shock wave therapy treatment.

Perhaps more significantly, the successful outcomes appear closely tied to asthma and a second study has been initiated focusing entirely on asthmatic horses. Of eight horses treated in the asthma study to date seven of the eight had 100% resolution of coughing in four weeks and the remaining horse had a 50% reduction in coughing. Approximately 15% of horses over the age of seven are affected by asthma which is currently treated by bronchodilators and/or drugs. The study results suggest that shock wave may present a non-invasive, non-pharmacological option for horses suffering from this affliction.

"Zomedica's PulseVet shock wave therapy has become a clinically proven option for many sports medicine indications such as tendon and ligament injuries, chronic back pain, and osteoarthritis, but it had not previously been studied in pulmonary indications. This study provides the basis to view shock wave therapy as a substantial new treatment modality for a challenging problem that may benefit not only the horse but potentially all species," said Dr. Whitaker.

Adrian Lock, VP of Clinical and Veterinary Affairs at Zomedica, stated, "we are extremely excited to see the early successful results of this research and proud to be able to support efforts that have now led to a significant new benefit that electrohydraulic shock wave therapy has been shown to provide."

Zomedica remains steadfast in its commitment to staying at the forefront of non-invasive, regenerative options in veterinary care. It's unwavering dedication to advancing veterinary care is demonstrated through its ongoing clinical studies, which have yielded promising results in various shock wave areas.